<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591071</url>
  </required_header>
  <id_info>
    <org_study_id>432</org_study_id>
    <nct_id>NCT00591071</nct_id>
  </id_info>
  <brief_title>Impact of 2 Blood Glucose Levels on Hospital Mortality in Patients Admitted in ICU</brief_title>
  <acronym>INSUREA</acronym>
  <official_title>Multicentre Randomized Trial Assessing the Impact of Maintaining 2 Blood Glucose Levels on Hospital Mortality in Patients Admitted to the ICU (INSUREA STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poissy-Saint Germain Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poissy-Saint Germain Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During hospitalization in the intensive care unit (ICU), the occurrence of a blood glucose&#xD;
      imbalance is frequent and associated with increased mortality. These observations have&#xD;
      resulted in the hypothesis that intensive insulin therapy designed to control blood glucose&#xD;
      would improve the prognosis of patients admitted into the ICU. In a prospective, randomized,&#xD;
      single center study in a surgical ICU during which the majority of patients had undergone&#xD;
      cardiac surgery, intensive insulin therapy with the objective to maintain glycemia below 110&#xD;
      mg/dl (6.1 mmol/L) provided a significant reduction in ICU mortality and hospital mortality&#xD;
      compared to a group with a glycemic objective of 200 mg/dl.&#xD;
&#xD;
      In a recent published article, the beneficial effect of intensive insulin therapy seems less&#xD;
      obvious in a randomized single center study in a medical ICU. One of the potential factors&#xD;
      limiting the impact of a therapeutic strategy like this one is the absence of achieving&#xD;
      strict glycemic control for all patients on intensive insulin therapy. Additionally, the&#xD;
      implementation of such a therapeutic strategy results in an increased risk of hypoglycemia,&#xD;
      the consequences of which on morbidity remain unclear.&#xD;
&#xD;
      The aim of our study is to determine, in a mixed population of medical and surgical patients&#xD;
      admitted to the ICU, requiring artificial ventilation with a expected duration above 48&#xD;
      hours, the impact of effective strict glycemic control (&lt;6,1 mmol/l) compared to a&#xD;
      conventional glycemic control (&lt;11mmol/l) on hospital mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In both randomization arms, continuous insulin infusion will be used via the venous route of&#xD;
      administration. Rapid action insulin Novorapid HM (Novo Nordisk, Copenhagen, Denmark) will be&#xD;
      used.&#xD;
&#xD;
      ICU patient management requires many intravenously administered treatments in a limited&#xD;
      number of venous lines (catecholamines, sedation, feeding, vascular filling, antioticsâ€¦).&#xD;
      This situation does not enable to dedicate an infusion line for the intravenous&#xD;
      administration of insulin. Despite continuous administration of insulin infusion, the&#xD;
      concomitant administration of other treatments in the same infusion line obviously leads to&#xD;
      significant variations in the flow of insulin actually delivered, which can lead to&#xD;
      variations in blood glucose and adjustments secondary to the inappropriate dose of insulin.&#xD;
      To limit this phenomenon, an OCTOPUS (Vygon, Ecouen, France) type infusion connector will be&#xD;
      added. The infusion connector is made of 2 infusion lines one of which will be exclusively&#xD;
      dedicated to insulin therapy subsequently limiting the risk of variations in insulin&#xD;
      administration flow.&#xD;
&#xD;
      The determination of the number of subjects to include was carried out by using a 45%&#xD;
      hospital mortality hypothesis in the conventional glycemic control group. and a 32 % hospital&#xD;
      mortality hypothesis in the strict glycemic control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">September 2010</completion_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>Length of hospital stay</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of severe hypoglycemia (below 2.2 mmol/l)</measure>
    <time_frame>lenght of insulin administration in ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>Length of ICU stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of obtained glycemic control in the 2 arms of the study</measure>
    <time_frame>Length of Continuous Insulin treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of neuromyopathy in the ICU</measure>
    <time_frame>Length of ICU stay</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Hyperglycemia</condition>
  <condition>Critically Ill Patients</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Strict glycemic control</intervention_name>
    <description>Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional glycemic control</intervention_name>
    <description>Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  over 18 years of age&#xD;
&#xD;
          -  requiring mechanical ventilation with an expected duration above 48 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  admission for cardiac arrest&#xD;
&#xD;
          -  admission for an attempt of drug autolysis or acute drunkenness&#xD;
&#xD;
          -  admission for hyperosmolar and/or ketoacidosis coma&#xD;
&#xD;
          -  admission for massive cerebral hemorrhage&#xD;
&#xD;
          -  admission from an another ICU&#xD;
&#xD;
          -  admission after surgery without any other organ failure than respiratory support (with&#xD;
             FiO2 below 50% and PeeP below 5cm H2O)&#xD;
&#xD;
          -  inclusion in an another interventional study&#xD;
&#xD;
          -  patient or next of kind refusal of study participation&#xD;
&#xD;
          -  pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude Lacherade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medico-surgical ICU Poissy Saint Germain Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Claude Lacherade, MD</last_name>
    <phone>33 1 39 27 52 02</phone>
    <email>jclacherade@chi-poissy-st-germain.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medico-surgical ICU Louise Michel Hospital</name>
      <address>
        <city>Evry</city>
        <zip>91014 Cedex</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andry Van de Louw, MD</last_name>
      <email>andry.vandelouw@ch-sud-francilien.fr</email>
    </contact>
    <investigator>
      <last_name>Andry Van de Louw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medico-surgical ICU Poissy Saint Germain Hospital</name>
      <address>
        <city>Poissy</city>
        <zip>78300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Claude Lacherade, MD</last_name>
      <phone>33 1 39 27 54 55</phone>
      <email>jclacherade@chi-poissy-st-germain.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Claude Lacherade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <last_update_submitted>February 13, 2008</last_update_submitted>
  <last_update_submitted_qc>February 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jean-Claude Lacherade MD</name_title>
    <organization>Poissy Saint Germain Hospital</organization>
  </responsible_party>
  <keyword>hyperglycemia</keyword>
  <keyword>insulin treatment</keyword>
  <keyword>intensive care</keyword>
  <keyword>hypoglycemia</keyword>
  <keyword>mechanical ventilation</keyword>
  <keyword>critically ill patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

